SeaStar Medical Holding Corp (ICU) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, SeaStar Medical Holding Corp's filing signal continuing positive.

SeaStar Medical Holding Corporation is a commercial-stage healthcare company focused on developing treatments for critically ill patients with organ failure. Its core technology is the Selective Cytopheretic Device (SCD), designed to neutralize over-active immune cells and mitigate the cytokine storm responsible for hyperinflammation. The company received FDA approval under a Humanitarian Device Exemption (HDE) for its pediatric SCD therapy, QUELIMMUNE, which it began commercializing in July 2024. SeaStar Medical is also conducting a pivotal clinical trial for its SCD therapy in critically ill adult patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). The SCD therapy has received six Breakthrough Device Designations from the FDA across various indications, potentially expediting its regulatory pathway.

Revenue is primarily driven by the sale of its pediatric SCD therapy, QUELIMMUNE, to hospitals. Future revenue is also anticipated from potential license or collaboration agreements and government grants.